Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$10.00
|
|
Provider: Wright Reports
|
$25.00
|
|
Provider: Wright Reports
|
$100.00
|
|
Provider: Stock Traders Daily
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
ArthroCare Corporation Announces Agreement In Principle To Settle Securities Class Action
ArthroCare Corporation announced that it has reached an agreement in principle to settle the private securities class action suits pending against the Company and two of its former officers. These suits were previously consolidated into the action titled In Re ArthroCare Corporation Securities Litigation, Case No. 1:08-cv-00574-SS (consolidated) in the U.S. District Court, Western District of Texas. The settlement, subject to final documentation and court approval, would settle all claims arising from the purchase or sale of ArthroCare securities of a class of all purchasers of ArthroCare common stock [and call options, and sellers of put options on ArthroCare common stock] between December 11, 2007 and February 18, 2009, inclusive (the Class), except those members of the Class who opt out, for a payment of $74 million to a settlement fund to be created for the settlement. If the settlement is approved, counsel for the plaintiff will apply for an award of attorneys` fees and reimbursement of expenses from the settlement fund.
Latest Developments for ArthroCare Corp
- ArthroCare Corporation Issues FY 2012 Revenue Guidance Below Analysts' Estimates-Conference Call
- ArthroCare Corporation Updates FY 2011 Revenue Guidance To A Range In Line With Analysts' Estimates-Conference Call
- ArthroCare Corporation Receives FDA Clearance for SpeedLock Knotless Fixation Device
- ArthroCare Corporation Lowers FY 2011 Revenue Guidance-Conference Call
Latest Key Developments in Advanced Medical Equipment
- GN Store Nord A/S Proposes FY 2011 Dividend of DKK 0.27 Per Share
- GN Store Nord A/S Issues FY 2012 Organic Growth and EBITA Guidance
- Boston Scientific Corp. Receives FDA Approval For Drug-Eluting Coronary Stent Use In Heart Attack Patients
- Volcano Corporation Issues FY 2012 Guidance; EPS Guidance Below Analysts' Estimates
- Share this
- Link this
- Digg this


Follow Reuters